ArticleBMC neurology2026
Siponimod for relapsing-remitting multiple sclerosis: a single-center, real-world cohort study in China.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSiponimod is a new-generation sphingosine-1-phosphate (S1P) receptor modulator that has demonstrated efficacy and tolerability in patients with secondary progressive multiple sclerosis (SPMS) in pivotal trial. However, real-world data on its use in relapsing-remitting MS (RRMS) remain limited. This study aimed to evaluate the effectiveness and safety of siponimod in RRMS patients in a real-world clinical setting.
methodsThis was a retrospective, single-center cohort study including RRMS patients treated with siponimod between September 2020 and May 2025. Effectiveness outcomes included annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS), and no evidence of disease activity (NEDA3) status. Cognitive and motor performance were explored in a predefined subgroup using the Symbol Digit Modalities Test (SDMT), 9-Hole Peg Test (9HPT), and Timed 25-Foot Walk (T25FW).
resultsAmong 77 RRMS patients identified, 68 who received siponimod for more than 6 months were included in the effectiveness analysis, including 52 treatment- naïve and 16 treatment-switched patients. In treatment- naïve patients, mean ARR decreased from 1.08 ± 0.70 to 0.10 ± 0.37 after a median treatment duration of 19.6 months (P < 0.001). Among treatment-switched patients, ARR decreased from 0.70 ± 0.50 to 0.03 ± 0.12 over a median follow-up of 23.7 months (P < 0.001). Median EDSS remained stable in both groups. At the last follow-up, the proportion achieving NEDA3 was comparable between treatment-naïve and switched group (65.4% vs. 62.5%). In exploratory subgroup analysis, siponimod was associated with a modest increase in SDMT scores and a small improvement in 9HPT performance, while no significant change was observed in T25FW. Lymphopenia was the most common adverse event, observed in 94.1% (64/68) of patients with available counts, with grade 3 lymphopenia in 61.8% (42/68).
conclusionsSiponimod was associated with reduced relapse activity and stable disability in patients with RRMS and may provide potential cognitive benefit. Given the high incidence of lymphopenia, close monitoring of peripheral lymphocyte counts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.